Elective laparoscopic cholecistectomy in a severe hemophilia A patient with inhibitors to factor VII
Santos, Alexandra*; Antunes, Margarida*; Diniz, M João*, Pimentel, Teresa
Hemophilia Centre, Hospital São José, Lisbon – Portugal

PATIENT PRESENTATION
- 38 years-old severe hemophilia A patient with genetic profile showing a stop mutation
- Inhibitors since he was 14, high titre
- HCV infection detected when he was 25 and treated with peginterferon α2a and ribavirin
- Treated on demand for bleeding episodes with either FEIBA® or Novoseven® since 1998, with similar clinical results
- Target-joint: right knee, with severe arthropaty

LAPAROSCOPIC PROTOCOL
- A laparoscopic cholecystectomy was performed without technical complications (Fig 1)
- The hemostasis of the liver bed was done with Tissuecoll®
- Surgical bleeding was considered normal
- Post-operative period without clinical problems.

rFVIIa PROTOCOL

<table>
<thead>
<tr>
<th>rFVIIa (bolus µg/Kg)</th>
<th>Pre &amp; intra-op.</th>
<th>Pos-op. &amp; D+1</th>
<th>D+2</th>
<th>D+3</th>
<th>D+4</th>
<th>D+5</th>
<th>D+6</th>
<th>D+7</th>
</tr>
</thead>
<tbody>
<tr>
<td>110</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>92</td>
<td>-</td>
<td>q2h</td>
<td>q3h</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>60</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>q3h</td>
<td>q4h</td>
<td>q4h</td>
<td>q6h</td>
<td>q12h</td>
</tr>
<tr>
<td>EACA (bolus)</td>
<td>5g 6/6h</td>
<td>3g 8/8h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total rFVIIa dose administrated: 287.6 mg

PRE-OPERATORY CLINICAL COURSE
- In the previous months he had recurrent episodes of acute lithiasic cholecistitis successfully managed with admission to hospital for conservative therapy
- Abdominal ultrasound revealed a persistent thickened gallbladder
- Proposed for laparoscopic surgery after pluridisciplinary and patient consensus
- A treatment protocol was scheduled using a bypassing agent - the activated recombinant factor VII Novoseven® (rFVIIa) - and acid ε-aminocaproic (EACA) as adjunctive hemostatic agent.

FINAL CONSIDERATIONS
- Elective surgery in hemophilia patients with inhibitors is a major undertaking, owing to the bleeding complications.
- rFVIIa proved to be efficacious in the initiation and maintenance of hemostasis during and after this elective surgery.
- The inhibitor titre had no anamnestic response.
- No adverse events were observed related to rFVIIa administration.
- The economic impact of this procedure was obviously taken into account, considered the improvement of the patient’s quality of life.

* Department of Imunohemotherapy
Department of Surgery